Login to Your Account



Financings Roundup


Wednesday, May 16, 2012
• Cytos Biotechnology Ltd., of Zurich, Switzerland, said it completed a CHF23.75 million (US$25.2 million) equity investment. The financing is part of a planned CHF37 million debt and equity deal to be provided by an international syndicate of investors, including venBio, Abingworth, Aisling Capital and Amgen. Cytos intends to use the proceeds primarily to conduct a Phase IIb study of CYT003 in allergic asthma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription